Related content

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets

By Ramondetta L.M.   Burke T.W.   Jhingran A.   Schmandt R.   Bevers M.W.   Wolf J.K.   Levenback C.F.   Broaddus R.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 529-536

Elsevier

Access to resources Recommend Favorite

Chemotherapy for Malignant Mixed Mullerian Tumors of the Ovary

By Sit A.S.Y.   Price F.V.   Kelley J.L.   Comerci J.T.   Kunschner A.J.   Kanbour-Shakir A.   Edwards R.P.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 196-200

Elsevier

Access to resources Recommend Favorite

Management of Uterine Mullerian Adenosarcoma with Extrauterine Metastatic Deposits

By Guidozzi F.   Smith T.   Koller A.B.   Reinecke L.  

Gynecologic Oncology, Vol. 77, Iss. 3, 2000-06 ,pp. : 464-466

Elsevier

Access to resources Recommend Favorite

Evidence for a Common Etiology for Endometrial Carcinomas and Malignant Mixed Mullerian Tumors

By Zelmanowicz A.   Hildesheim A.   Sherman M.E.   Sturgeon S.R.   Kurman R.J.   Barrett R.J.   Berman M.L.   Mortel R.   Twiggs L.B.   Wilbanks G.D.   Brinton L.A.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 253-257

Elsevier

Access to resources Recommend Favorite

Paclitaxel and Platinum Chemotherapy for Malignant Mixed Mullerian Tumors of the Ovary

By Duska L.R.   Garrett A.   Eltabbakh G.H.   Oliva E.   Penson R.   Fuller A.F.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 459-463

Academic Press

Access to resources Recommend Favorite